Drug intelligence / Profile preview

Soriacare

Development stage: Preclinical
Lead developer: Issar Pharmaceuticals
Modality: Peptides
Administration: Topical

Overview

Soriacare (IS-217) is a peptide-based new chemical entity (NCE) developed by Issar Pharmaceuticals for the treatment of psoriasis. It is a topical formulation designed to exert anti-angiogenic and anti-inflammatory effects through the modulation of the vascular endothelial growth factor receptor (VEGFR) and inflammatory pathways, including p38 mitogen-activated protein kinase (p38 MAPK) and myeloperoxidase (MPO). As a peptide-based therapeutic, it represents part of Issar Pharmaceuticals' focus on peptide drug discovery for unmet medical needs. The drug is currently in clinical development in India and has been submitted for clinical evaluation with the US FDA.

Brand names: Soriacare

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)MPO (Myeloperoxidase)VEGFR (VEGFR family)

Beyond the preview

Go deeper on Soriacare.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soriacare.

Explore the full profile